NATCO Pharma
Market cap ₹16,098 Cr
- P/E
- 17.88
- Day range
- ₹818.10 – ₹832.85
- 52-week range
- ₹773.60 – ₹1,226.80
- Volume
- 11.14 L
- Open
- ₹823.80
- Prev close
- ₹822.90
Latest results · Q2 FY27(consolidated)Revenue ₹967 Cr-29.0%Profit ₹203 Cr-60.9%Margin 20.9%YoY vs the same quarter last year
3 red flags to read up on
- medium
Promoter pledge went up
0.94% of promoter shares pledged, up from 0.00% · 23 Oct 2026
- medium
Promoters selling in the market
Promoter group sold a net ₹5.0 Cr on the open market in 90 days · 14 Oct 2026
- medium
Promoter holding falling
46.22%, down 3.26 pts since 2025-12-31 · 23 Oct 2026
From NSE and BSE filings. A flag is a reason to read the filing, not a rating.
NATCOPHARM in NSE indices and F&O
Research profile
Factor percentiles
Derived metrics
- Earn. yield
- 5.6%
- Graham no.
- ₹713.88
- vs Graham
- -13.0%
- ROE ÷ P/B
- 11.0%
- Magic Formula
- #147
- Piotroski
- 1/6
- FCF yield
- 8.6%
Appears in 4 scans
Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.
Peer comparison
All 68 in Pharma| Company | M-cap | P/E | P/B | ROE | ROCE | OPM | D/E | Sales YoY |
|---|---|---|---|---|---|---|---|---|
| Sun PharmaSUNPHARMA | ₹4.49 L Cr | 40.95 | 5.03 | 14.8% | 21.0% | 29.0% | 0.04 | +11.9% |
| Divi's LaboratoriesDIVISLAB | ₹2.93 L Cr | 87.19 | 16.88 | 16.2% | 22.0% | 43.0% | 0.00 | +35.4% |
| Torrent PharmaTORNTPHARM | ₹1.75 L Cr | 77.88 | 9.67 | 26.8% | 15.0% | 33.0% | 0.77 | +50.8% |
| Apollo HospitalsAPOLLOHOSP | ₹1.27 L Cr | 56.40 | 11.55 | 22.6% | 17.0% | 16.0% | 0.77 | +23.0% |
| Laurus LabsLAURUSLABS | ₹1.25 L Cr | 93.72 | 19.82 | 18.2% | 18.0% | 34.0% | 0.43 | +33.5% |
| Zydus LifesciencesZYDUSLIFE | ₹1.20 L Cr | 28.72 | 4.32 | 20.1% | 21.0% | 24.0% | 0.50 | +29.2% |
| Dr. Reddy's LabsDRREDDY | ₹1.17 L Cr | 41.63 | 2.97 | 11.6% | 13.0% | 20.0% | 0.19 | -1.5% |
| NATCO PharmaNATCOPHARM | ₹16,098 Cr | 17.88 | 1.53 | 16.9% | 17.0% | 27.0% | 0.11 | -29.1% |
| Sector median | ₹24,603 Cr | 43.68 | 5.46 | 15.1% | 17.0% | 24.0% | 0.17 | +22.7% |
Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.
Latest news
Updated 1d agoHeadlines about NATCO Pharma from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.
Key metrics
- P/E (TTM)
- 19.6
- Price / Book
- 1.52
- ROE (FY26)
- 16.9%
- ROCE (latest year)
- 17%
- Dividend yield
- 0.60%
Charts & trends
From company filings. Amounts in ₹ crore.
Revenue, profit & margin - quarterly
₹ crore; a loss shows red. Operating margin below, same periods.
- Revenue
- Net profit
Operating margin
Who owns the company
% of equity by quarter, latest Oct 2026
- Promoter
- Public
- FII
- DII
Cash flows
Where cash came from and went, by fiscal year (₹ crore)
- Operating
- Investing
- Financing
- Free cash flow
Return on equity
Net profit over shareholders' equity, by fiscal year
Equity vs debt
Shareholders' equity against borrowings (₹ crore); the ratio below, same years.
- Equity
- Debt
Debt to equity
Dividends per share
₹ by fiscal year of the ex-date; the latest year runs to date.
Financial statements
| Line item | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 759 | 1,068 | 1,363 | 1,371 | 475 | 1,221 | 1,329 | 1,363 | 647 | 739 | 735 | 967 |
| YoY Sales growth | — | — | — | — | -37 | — | -2 | -1 | — | -39 | -45 | -29 |
| Expenses | 490 | 571 | 558 | 567 | 436 | 673 | 758 | 784 | 489 | 612 | 549 | 709 |
| Operating Profit | 268 | 497 | 805 | 804 | 39 | 548 | 571 | 579 | 159 | 128 | 186 | 258 |
| OPM % | 35% | 47% | 59% | 59% | 8% | 45% | 43% | 42% | 25% | 17% | 25% | 27% |
| Other Income | 37 | 42 | 48 | 64 | 176 | 66 | 62 | 100 | 58 | 78 | 59 | 52 |
| Interest | 5 | 6 | 5 | 4 | 4 | 10 | 3 | 13 | 10 | 11 | 13 | 18 |
| Depreciation | 44 | 56 | 44 | 46 | 47 | 98 | 58 | 52 | 46 | 50 | 47 | 49 |
| Profit before tax | 256 | 478 | 804 | 818 | 164 | 506 | 572 | 614 | 161 | 144 | 186 | 243 |
| Tax % | 17% | 19% | 17% | 17% | 19% | 20% | 16% | 16% | 13% | -62% | 34% | 29% |
| Net Profit | 213 | 386 | 668 | 676 | 132 | 406 | 480 | 518 | 151 | 269 | 206 | 203 |
| EPS in Rs | ₹11.78 | ₹21.39 | ₹37.02 | ₹37.50 | ₹7.36 | ₹22.51 | ₹26.62 | ₹28.70 | ₹8.39 | ₹14.83 | ₹11.43 | ₹11.22 |
From company filings, updated 17 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.
Working-capital cycle
+6 days since Mar 2021
-90 days since Mar 2021
+112 days since Mar 2021
-196 days since Mar 2021
-135 days since Mar 2021
Strengths, risks & growth
NATCO Pharma Limited (NATCO) is a vertically integrated, research and development focused pharmaceutical company engaged in developing, manufacturing, and marketing complex products for niche therapeutic areas. [1] NATCO has established its presence in all three business segments viz. finished dosage formulations (“FDF”), active pharmaceutical ingredients (“APIs”), Contract Manufacturing Business. [2]
Strengths
- Company has delivered good profit growth of 28.1% CAGR over last 5 years
Risks
- Promoter holding has decreased over last quarter: -3.19%
- Tax rate seems low
- Earnings include an other income of Rs.247 Cr.
Compounded Sales Growth
- 10 Years
- +15%
- 5 Years
- +15%
- 3 Years
- +15%
- TTM
- -30%
Compounded Profit Growth
- 10 Years
- +25%
- 5 Years
- +28%
- 3 Years
- +27%
- TTM
- -46%
Stock Price CAGR
- 10 Years
- +3%
- 5 Years
- +1%
- 3 Years
- +2%
- 1 Year
- +2%
Return on Equity
- 10 Years
- +19%
- 5 Years
- +19%
- 3 Years
- +23%
- Last Year
- +17%
Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.
Shareholding pattern
| Holder | Mar 2026 | Jun 2026 | Sept 2026 | Oct 2026 | Change |
|---|---|---|---|---|---|
| Promoter | 49.41% | 49.41% | 49.39% | 46.22% | -3.17 pp |
| FII | 17.37% | 16.99% | 15.99% | 15.37% | -0.62 pp |
| DII | 5.46% | 5.63% | 6.16% | 10.82% | +4.66 pp |
| Public | 27.74% | 27.97% | 28.46% | 27.59% | -0.87 pp |
Filed with NSE for Oct 2026: promoters 46.22%, public 53.78%
Analysts & fund holdings
Who holds the shares, quarter by quarter
Mutual funds 7.01% (+4.76 pp)- Promoters46.2%
- Foreign institutions15.4%
- Mutual funds7.0%
- Insurance3.6%
- Other domestic institutions0.2%
- Retail19.6%
- Others8.0%
| Fund | % of company | % of fund | 3-month change |
|---|---|---|---|
| Tata Small Cap Fund | 1.25% | 1.72% | +1.32 pp |
| ICICI Pru Contra Fund | 0.64% | 6.59% | +6.59 pp |
| Nippon India Growth Mid Cap Fund | 0.52% | 0.17% | +0.17 pp |
| Nippon India Pharma Fund | 0.50% | 0.90% | +0.90 pp |
| ICICI Pru Manufacturing Fund | 0.46% | 1.14% | +1.14 pp |
Scorecard
- Performance
- Low
- Valuation
- High
- Growth
- Avg
- Profitability
- High
- Entry point
- Good
- Red flags
- Low
Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.
Financial quality
From consolidated statements to 31 Mar 2026.
Piotroski F-Score
1 of 6 tested
- Return on assets positive — passed
- Operating cash flow positive — not testableno cash flow statement for this period
- Return on assets improving — failed
- Cash flow exceeds profit — not testableneeds cash flow and profit against assets
- Debt to assets falling — failed
- Current ratio improving — failed
- No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
- Operating margin improving — failed
- Asset turnover improving — failed
- Free cash flow
- ₹1,377 Cr
- FCF yield
- 8.6%
- Cash conversion
- 1.25
- Accruals ratio
- -0.032
- Net debt
- ₹515 Cr
- Net debt / equity
- 0.06
- EV / sales
- 5.38
- Capex intensity
- 9.6%
- Revenue CAGR
- -39.5%
- Profit CAGR
- -33.7%
Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.
Insider trades
| Person | Type | Shares | Value | Disclosed |
|---|---|---|---|---|
VENKAIAH CHOWDARY NANNAPANENI Promoter and Director · Allotment | Buy | 5,86,666 | ₹44.0 Cr | 29 Oct 2026 |
NEELIMA SITA NANNAPANENI Promoter · Allotment | Buy | 2,55,387 | ₹19.2 Cr | 29 Oct 2026 |
RAJEEV NANNAPANENI Promoter and Director · Allotment | Buy | 58,666 | ₹4.4 Cr | 29 Oct 2026 |
TIME CAP PHAMA LABS PVT LTD Promoter Group · Allotment | Buy | 9,33,333 | ₹70.0 Cr | 29 Oct 2026 |
NATSOFT INFORMATION SYSTEMS PVT LTD Promoter Group · Allotment | Buy | 2,40,000 | ₹18.0 Cr | 29 Oct 2026 |
NATCO AQUA LIMITED Promoter Group · Allotment | Buy | 1,523 | ₹11.4 L | 29 Oct 2026 |
VISTRA ITCL LIMITED A/C NEELIMA TRUST Promoter · Allotment | Buy | 69,785 | ₹5.2 Cr | 29 Oct 2026 |
VISTRA ITCL LIMITED A/C VCN FAMILY TRUST Promoter · Allotment | Buy | 161 | ₹1.2 L | 29 Oct 2026 |
SAU FAMILY TRUST Promoter · Allotment | Buy | 161 | ₹1.2 L | 29 Oct 2026 |
V S SWATHI KANTAMANI Promoter Group · Allotment | Buy | 61,333 | ₹4.6 Cr | 29 Oct 2026 |
KANTAMANI RATNA KUMAR Promoter Group · Allotment | Buy | 4,761 | ₹35.7 L | 29 Oct 2026 |
LINGARAO DONTHINENI Director · Allotment | Buy | 5,157 | ₹38.7 L | 29 Oct 2026 |
Disclosures filed with NSE under SEBI (Prohibition of Insider Trading) Regulations. Pledges and releases are not trades and are not counted above.
Corporate actions
- dividend₹1.25
Interim Dividend - Rs 1.25 Per Share
19 Nov 2026ex-date - rightsNot available — not reported in this filing
Rights 2:21 @ Premium Rs 748/-
1 Oct 2026ex-date - dividend₹1.50
Interim Dividend - Rs 1.50 Per Share
20 Aug 2026ex-date - dividend₹1.50
Interim Dividend - Rs 1.50 Per Share
18 Feb 2026ex-date - dividend₹1.50
Interim Dividend - Rs 1.50 Per Share
20 Nov 2025ex-date - dividend₹2.00
Interim Dividend - Rs 2 Per Share
19 Aug 2025ex-date - dividend₹1.50
Interim Dividend - Rs 1.50 Per Share
18 Feb 2025ex-date - dividend₹1.50
Interim Dividend - Rs 1.50 Per Share
27 Nov 2024ex-date - otherNot available — not reported in this filing
Annual General Meeting
25 Sept 2024ex-date - dividend₹3.00
Interim Dividend - Rs 3 Per Share
23 Aug 2024ex-date - dividend₹1.25
Interim Dividend - Rs 1.25 Per Share
26 Feb 2024ex-date - dividend₹1.25
Interim Dividend - Rs 1.25 Per Share
24 Nov 2023ex-date - otherNot available — not reported in this filing
Annual General Meeting
25 Sept 2023ex-date - dividend₹7.00
Interim Dividend - Rs 7 Per Share
22 Aug 2023ex-date - dividend₹1.25
Interim Dividend - Rs 1.25 Per Share
21 Feb 2023ex-date - dividendNot available — not reported in this filing
Interim Dividend - Re 0.75 Per Share
21 Nov 2022ex-date - otherNot available — not reported in this filing
Annual General Meeting
23 Sept 2022ex-date - dividend₹3.50
Interim Dividend - Rs 3.50 Per Share
19 Aug 2022ex-date - dividend₹2.00
Interim Dividend - Rs 2 Per Share
24 Feb 2022ex-date - dividend₹0.50
Interim Dividend - Rs 0.50 Per Share
23 Nov 2021ex-date - otherNot available — not reported in this filing
Annual General Meeting
23 Sept 2021ex-date
Company announcements
Update on Trading Window Closure period
Intimation of closure of the Issue period of the Rights Issue of NATCO Pharma Limited (the "Company")
Natco Pharma announces launch of Carboplatin Injection (generic of Paraplatin) in the U.S. market
Compliance Certificate under Reg.74(5) of SEBI(DP) Regulations, 2018
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on October 12, 2026 for V C Nannapaneni
News Paper Publications
Evoting Results along with Scrutinizer Report for the 43rd Annual General Meeting held on 30/09/2026
Proceedings of the 43rd Annual General Meting
Outcome of Fund Raising Committee Meeting approving the Letter of Offer for Rights Issue
Press Release and disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015
Newspaper Publication of Record date for Rights Issue
Intimation of Record Date for Rights Issue
Out come of Board Meeting
Natco Pharma Limited has informed the Exchange that Board of Directors at its meeting held on September 25, 2026, has decided to issue equity shares on rights basis in the ratio of 2 : ....
Filed with BSE (scrip 524816); the last 45 days. Documents open at bseindia.com.
SEBI filings & orders
From SEBI's website. An order may concern the company, its officers or trading in its shares, and may be under appeal - read the order itself. Personal identifiers are withheld.
Buybacks, open offers & rights issues
- Buyback
NATCO Pharma Limited
10 Mar 2023Read on SEBI - Buyback - Corrigendum to Public Announcement
Natco Pharma Limited – Corrigendum to Public Announcement
19 Mar 2019Read on SEBI - Buyback - Public Announcement
Natco Pharma Limited – Public Announcement
14 Nov 2018Read on SEBI - Open offer
Natco Pharma Limited
5 Feb 2007Read on SEBI - Buyback - Public Announcement
Natco Pharma Limited - Public Announcement
6 Sept 2006Read on SEBI
Regulatory orders
- Order
Order in the matter of Natco Pharma Limited
5 Jan 2007Read on SEBI
Documents
Annual reports
Earnings calls
- Nov 2026SlidesRecording
- Aug 2026TranscriptSlides
- Aug 2026SlidesRecording
- Jun 2026TranscriptSlidesRecording
- Feb 2026TranscriptSlidesRecording
- Nov 2025TranscriptSlidesRecording
Credit ratings
- Rating update · 28 Nov 2025 from icra
- Rating update · 1 Aug 2025 from icra
- Rating update · 29 Apr 2025 from icra
- Rating update · 30 Apr 2024 from icra
- Rating update · 28 Apr 2023 from icra
- Rating update · 28 Apr 2022 from icra
Documents open at BSE or the rating agency that issued them.
Sourced from the company's NSE XBRL filing dated 13 Nov 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.
NATCO Pharma: common questions
Answered from the figures on this page.